Literature DB >> 11171960

Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.

N de Paulsen1, A Brychzy, M C Fournier, R D Klausner, J R Gnarra, A Pause, S Lee.   

Abstract

Mutations of the VHL tumor suppressor gene occur in patients with VHL disease and in the majority of sporadic clear cell renal carcinomas (VHL(-/-) RCC). Loss of VHL protein function is associated with constitutive expression of mRNAs encoding hypoxia-inducible proteins, such as vascular endothelial growth factor. Overproduction of angiogenic factors might explain why VHL(-/-) RCC tumors are so highly vascularized, but whether this overproduction is sufficient for oncogenesis still remains unknown. In this report, we examined the activity of transforming growth factor-alpha (TGF-alpha), another VHL-regulated growth factor. We show that TGF-alpha mRNA and protein are hypoxia-inducible in VHL(-/-) RCC cells expressing reintroduced VHL. In addition to its overexpression by VHL(-/-) RCC cells, TGF-alpha can also act as a specific growth-stimulatory factor for VHL(-/-) RCC cells expressing reintroduced wild-type VHL, as well as primary renal proximal tubule epithelial cells, the likely site of origin of RCC. This role is in contrast to those of other growth factors overexpressed by VHL(-/-) RCC cells, such as vascular endothelial growth factor and TGF-beta1, which do not stimulate RCC cell proliferation. A TGF-alpha-specific antisense oligodeoxynucleotide blocked TGF-alpha production in VHL(-/-) RCC cells, which led to the dependence of those cells on exogenous growth factors to sustain growth in culture. Growth of VHL(-/-) RCC cells was also significantly reduced by a drug that specifically inhibits the epidermal growth factor receptor, the receptor through which TGF-alpha stimulates proliferation. These results suggest that the generation of a TGF-alpha autocrine loop as a consequence of VHL inactivation in renal proximal tubule epithelial cells may provide the uncontrolled growth stimulus necessary for the initiation of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171960      PMCID: PMC29266          DOI: 10.1073/pnas.98.4.1387

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Cancer-susceptibility genes. Gatekeepers and caretakers.

Authors:  K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

2.  Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.

Authors:  M Kovalenko; A Gazit; A Böhmer; C Rorsman; L Rönnstrand; C H Heldin; J Waltenberger; F D Böhmer; A Levitzki
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

3.  Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.

Authors:  B Knebelmann; S Ananth; H T Cohen; V P Sukhatme
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

4.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.

Authors:  A Pause; S Lee; K M Lonergan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

5.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.

Authors:  J R Gnarra; S Zhou; M J Merrill; J R Wagner; A Krumm; E Papavassiliou; E H Oldfield; R D Klausner; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

6.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

Authors:  G Siemeister; K Weindel; K Mohrs; B Barleon; G Martiny-Baron; D Marmé
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

8.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.

Authors:  M Ohh; R L Yauch; K M Lonergan; J M Whaley; A O Stemmer-Rachamimov; D N Louis; B J Gavin; N Kley; W G Kaelin; O Iliopoulos
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

9.  Tumour suppression by the human von Hippel-Lindau gene product.

Authors:  O Iliopoulos; A Kibel; S Gray; W G Kaelin
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

10.  Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S Pepe; A R Bianco; S Agrawal; J Mendelsohn; G Tortora
Journal:  J Natl Cancer Inst       Date:  1998-07-15       Impact factor: 13.506

View more
  53 in total

1.  An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: four associated with von Hippel-Lindau disease and one aggressive sporadic type.

Authors:  Francisco F Nogales; Pablo Goyenaga; Ovidiu Preda; Alina Nicolae; Begoña Vieites; Maria Carmen Ruiz-Marcellan; Alberto Pedrosa; Maria J Merino
Journal:  Histopathology       Date:  2012-02-01       Impact factor: 5.087

2.  Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer.

Authors:  Aleksandra Franovic; Lakshman Gunaratnam; Karlene Smith; Isabelle Robert; David Patten; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

3.  Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Authors:  Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Targeted therapy for renal cell carcinoma: a new treatment paradigm.

Authors:  Thomas E Hutson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

Review 5.  Novel approaches in the therapy of metastatic renal cell carcinoma.

Authors:  John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Journal:  World J Urol       Date:  2005-04-05       Impact factor: 4.226

6.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells.

Authors:  Rusha Thomas; Myoung H Kim
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

8.  Human cancers converge at the HIF-2alpha oncogenic axis.

Authors:  Aleksandra Franovic; Chet E Holterman; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

Review 9.  Molecular basis for the treatment of renal cell carcinoma.

Authors:  Cristina Suárez; Rafael Morales; Eva Muñoz; Jordi Rodón; Claudia M Valverde; Joan Carles
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

10.  Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein.

Authors:  Li Lei; Steve Mason; Dinggang Liu; Yan Huang; Carolyn Marks; Reed Hickey; Ion S Jovin; Marc Pypaert; Randall S Johnson; Frank J Giordano
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.